Amit K. Verma

https://assets.montefioreeinstein.org/profiles/images/Verma_Amit_MD_2x.jpg

First Name

Amit

Last Name

Verma

NPI

1033299524

Faculty ID

10065

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>https://einsteinmed.edu/labs/amit-verma/</p&gt;
<p><strong style="text-align: justify;">Targeting signal transduction in hematologic malignancies</strong><span style="text-align: justify;">:&nbsp;<br /></span><span style="text-align: justify;">Cytokines play important roles in the regulation of normal hematopoiesis and a balance between the actions of hematopoietic growth factors and myelosuppressive factors is required for optimal production of different hematopoietic cell lineages. The myelodysplastic syndromes (MDS) are collections of heterogeneous hematologic diseases characterized by refractory cytopenias due to ineffective hematopoiesis. These preleukemic disorders are common causes of anemia in the elderly and are rapidly increasing in incidence. We have also demonstrated that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways is overactivated in MDS. Our work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. We are trying to study the molecular mechanisms that lead to the activation of these pathways in MDS and are using small molecule inhibitors in mouse models to target these pathways.&nbsp;</span></p>
<p style="text-align: justify;"><strong>Targeting aberrant stem and progenitor cells in myelodysplastic neoplasms:&nbsp;<br /></strong>We have demonstrated that aberrant stem cells persist during morphological remissions and are involved in relapse. We have identified novel targets against MDS/AML stem cells that are being tested in various studies. We are also conducting sequencing/epigenetic analysis of highly purified human stem cells and evaluating the role of these alterations in transformation of MDS to AML.&nbsp;</p>
<p style="text-align: justify;"><strong>Epigenomic analysis of tumors</strong>: <br />We are using high throughput assays to analyze DNA methylation across the genome and have optimized these assays to work with low amounts of DNA. We have successfully used these assays in conducting an integrative analysis of epigenetic and genetic alterations in various tumor models, including MDS, esophageal cancer, pancreatic cancer and renal cell cancer.</p>
<p style="text-align: justify;"><strong>Clinical studies in Myelodysplastic syndromes</strong>: <br />We have a &ldquo;center of excellence&rdquo; clinic for patients with Myelodysplatic syndromes. We offer a variety of clinical trials for these patients.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Verma is a blood cancer expert, who specializes in the research and treatment of blood cancers.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Verma conducts clinical studies for patients with MDS and leukemia and offers a variety of clinical trials for these patients.

Research Focus

Dr. Verma conducts laboratory research aimed at discovering new treatments for myelodysplastic syndromes (MDS) and leukemias, and his research has shown that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways are overactivated in MDS. His work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. DR. Verma’s research has shown that MDS and leukemias are caused by aberrant leukemic stem cells and has identified novel targets against MDS/AML stem cells that are being tested in various studies. 

Elsevier Profile

Lab Website Link

Selected Publications

<ol>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/40424086/&quot; target="_blank">Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes.</a><br/>Aluri S, Ling T, Fraint E, Chakraborty S, Zhang K, Ahsan A, Kravets L, Poigaialwar G, Zhao R, Pradhan K, Cotton A, Bachiashvili K, Yang JI, Budhathoki A, Agarwal B, Gordon-Mitchell S, Carbajal M, Sahu S, Boultwood J, Pellagatti A, Steidl U, Wickrema A, Nandakumar S, Shastri A, Suragani RN, Bowman TV, Crispino JD, Vodala S, <strong>Verma A. J Clin Invest.</strong> 2025 May 27. PMID: 40424086.</li>

<li><a href="https://pubmed.ncbi.nlm.nih.gov/40333990/&quot; target="_blank">Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias.</a><br/>Venkatasubramanian M, Schwartz L, Ramachandra N, Bennett J, Subramanian KR, Chen X, Gordon-Mitchell S, Fromowitz A, Pradhan K, Shechter D, Sahu S, Heiser D, Scherle P, Chetal K, Kulkarni A, Lee D, Zhou J, Myers KC, Tseng E, Weirauch MT, Grimes HL,* Starczynowski DT,* <strong>Verma A</strong>,* Salomonis N.* <strong>Sci Transl Med</strong>. 2025 May 7. PMID: 40333990. *Co Corresponding</li>

<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39316768/&quot; target="_blank">A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort.</a><br />
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica A, Kornblum N, Shah N, Levitz D, Rockwell B, Shapiro LC, Gupta R, Pradhan K, Xue X, Munoz A, Dhawan A, Fehn K, Comas M, Verceles JA, Jonas BA, Kambhampati S, Shi Y, Braunschweig I, Cooper DL, Konopleva MY, Feldman EJ, <strong>Verma A. <br />
<em>Blood</em></strong>. 2024 Sep 24.PMID: 39316768 </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39300320/&quot; target="_blank">Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.</a><br />
DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, <strong>Verma A*</strong>, Konopleva M*.<br />
<strong><em>Nat Cancer</em></strong>. 2024 Sep 19. PMID: 39300320 <br />
*CoCorresponding </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39294495/&quot; target="_blank">Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activity.</a><br />
Taylor SJ, Stauber J, Bohorquez O, Tatsumi G, Kumari R, Chakraborty J, Bartholdy BA, Schwenger E, Sundaravel S, Farahat AA, Wheat JC, Goldfinger M, <strong>Verma A</strong>, Kumar A, Boykin DW, Stengel KR, Poon GMK, Steidl U.<br />
<strong><em>Nat Genet</em></strong>. 2024 Sep 18. PMID: 39294495 </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/38521065/&quot; target="_blank">Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape.</a><br />
Boddu PC, Gupta AK, Roy R, De La Peña Avalos B, Olazabal-Herrero A, Neuenkirchen N, Zimmer JT, Chandhok NS, King D, Nannya Y, Ogawa S, Lin H, Simon MD, Dray E, Kupfer GM, <strong>Verma A</strong>, Neugebauer KM, Pillai MM. <strong><em>Mol Cell</em></strong>. 2024 Apr 18;84(8):1475-1495.e18.PMID: 38521065 </li>
<li> Aminov S*, Giricz O*, Melnekoff DT*, Sica RA*, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN^, Parekh S^, <strong>Verma A</strong>^ Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency <em><strong>JCI</strong></em>, 2024 Feb 20 PMID: 38376944 </li>
<li> Thakkar A, Pradhan K, Duva B, Carre&ntilde;o JM, Sahu S, Thiruthuvanathan V, Campbel S, Gallego S, Bhagat TD, Rivera J, Choudhary G, Olea R, Sabalza M, Shapiro LC, Lee M, Quinn R, Mantzaris I, Chu E, Will B, Pirofski LA, Krammer F, <strong>Verma A</strong>*, Halmos B*&nbsp; Study of efficacy and longevity of immune response to 3rd and 4th doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial&nbsp; <em><strong>Elife</strong></em> 2023, Mar 28;12:e83694. PMID: 36975207 </li>
<li> Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, <strong>Verma A,</strong> Feldman EJ, Goldfinger M. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML. <em><strong>Clin Cancer Res.</strong></em> 2023 Aug 1;29(15):2774-2780. PMID: 37341641. </li>
<li> Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT*, <strong>Verma A</strong>*. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. <strong>Elife</strong></em>. 2022 Aug 30;11:e78136. PMID: 36040792; PMCID: PMC9427103. </li>
<li>Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, Silver AJ, Chen J, Sahu S, Gordon-Mitchell S, Choudhary GS, Aluri S, Bhagat TD, Shastri A, Bejan CA, Stockton SS, Spaulding TP, Thiruthuvanathan V, Goto H, Gerhardt J, Haider SH, Veerappan A, Bartenstein M, Nwankwo G, Landgren O, Weiden MD, Lekostaj J, Bender R, Fletcher F, Greenberger L, Ebert BL, Steidl U, Will B, Nolan A, Madireddy A, Savona MR, Prezant DJ, <strong>Verma A</strong>. High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. <strong><em>Nat Med</em></strong>. 2022 Mar 7. PMID: 35256801.</li>
<li>Lee M, Quinn R, Pradhan K, Fedorov K, Levitz D, Fromowitz A, Thakkar A, Shapiro LC, Kabarriti R, Ruiz RE, Andrews EM, Thota R, Chu E, Kalnicki S, Goldstein Y, Loeb D, Racine A, Halmos B, Mehta V, <strong>Verma A</strong>. Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. <strong><em>Cancer Cell.</em></strong> 2022 Feb 22: PMID: 35219358; PMCID: PMC8860706</li>
<li>Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M, Sica RA, Goldfinger M, Goel S, Anampa JD, Levitz D, Fromowitz A, Shah AP, Sklow C, Alfieri G, Racine A, Wolgast L, Greenberger L, <strong>Verma A</strong>*, Halmos B*. *Co-Corresponding Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. <strong><em>Cancer Cell</em></strong>. 2022 Jan 10;40(1):3-5. PMID: 34838186; PMCID: PMC8595142.</li>
<li>Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, D&iacute;ez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, <strong>Verma A</strong>. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <strong><em>Leukemia.</em></strong> 2022 Feb 26. PMID: 35220402.</li>
<li>Pinho S, Wei Q, Maryanovich M, Zhang D, Balandr&aacute;n JC, Pierce H, Nakahara F, Di Staulo A, Bartholdy BA, Xu J, Borger DK,<strong> Verma A</strong>, Frenette PS. VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells. <strong><em>Nat Cell Biol</em></strong>. 2022 Feb 24. PMID: 35210567.</li>
<li>Myer PA, Lee JK, Madison RW, Pradhan K, Newberg JY, Isasi CR, Klempner SJ, Frampton GM, Ross JS, Venstrom JM, Schrock AB, Das S, Augenlicht L, <strong>Verma A</strong>, Greally JM, Raj SM, Goel S, Ali SM. The Genomics of Colorectal Cancer in Populations with African and European Ancestry. <strong><em>Cancer Discov.</em></strong> 2022 Feb 17: PMID: 35176763.</li>
<li>Su H, Jiang M, Senevirathne C, Aluri S, Zhang T, Guo H, Xavier-Ferrucio J, Jin S, Tran NT, Liu SM, Sun CW, Zhu Y, Zhao Q, Chen Y, Cable L, Shen Y, Liu J, Qu CK, Han X, Klug CA, Bhatia R, Chen Y, Nimer SD, Zheng YG, Iancu-Rubin C, Jin J, Deng H, Krause DS, Xiang J, <strong>Verma A*</strong>, Luo M*, Zhao X*. Methylation of dual-specificity phosphatase 4 controls cell differentiation. <em><strong>Cell Rep.</strong></em> 2021 Jul 27;36(4):109421. PMID: 34320342. *Co-Corresponding.</li>
<li>Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, <strong>Verma A*</strong>, Halmos B*. Seroconversion rates following COVID-19 vaccination among patients with cancer. <em><strong>Cancer Cell</strong></em>. 2021 Jun 5: PMID: 34133951; PMCID: PMC8179248. *Co-Corresponding</li>
<li>Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Pellagatti A, Boultwood J, Xiong S, Lozano G, <strong>Verma A</strong>, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. <em><strong>Cancer Cell</strong></em>. 2021 Apr 12;39(4):529-547.e7. PMID: 33667384.</li>
<li>Weinreb JT, Ghazale N, Pradhan K, Gupta V, Potts KS, Tricomi B, Daniels NJ, Padgett RA, Oliveira SD, <strong>Verma A</strong>, Bowman TV Excessive R-loops Trigger an Inflammatory Cascade Leading to Increased HSPC Production <em><strong>Dev Cell</strong></em>, 2021, Mar 8;56(5):627-640. PMID: 33651979.</li>
<li>Shapiro LC, Mustafa J, Lombardo A, Khatun F, Joseph F, Gillick K, Naik A, Elkind R, Abreu M, Fehn K, de Castro A, Pradhan K, Binakaj D, Nelson R, Paroder M, Uehlinger J, Gritsman K, Alejandro Sica R, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, <strong>Verma A</strong>, Braunschweig I, Goldfinger M. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population. <em><strong>Bone Marrow Transplant</strong></em>. 2021 Jul;56(7):1761-1763. PMID: 33846558.</li>
<li>Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, <strong>Verma A</strong>, Goel S, Halmos B Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anti-cancer therapy <em><strong>Nature Cancer</strong></em>, 2021, 2: 392&ndash;399.</li>
<li>Mehta V*, Goel S*, Kabarriti R*, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B*, <strong>Verma A*</strong>. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. <em><strong>Cancer Discov</strong></em>. 2020 Jul;10(7):935-941. PMID: 32357994; PMCID: PMC7334098.</li>
<li>List AF, Sun Z, <strong>Verma A*</strong>, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman J, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar T, Artz AA, Schiffer CA, Litzow MR, Tallman MS Lenalidomide-Epoetin Alfa versus Lenalidomide-monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin <em><strong>JCO</strong></em>, 2021, Jan 13: PMID: 33439748 *Corresponding.</li>
<li>COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <em><strong>Cancer Cell</strong></em>. 2020 Dec 14;38(6):761-766. PMID: 33176160; PMCID: PMC7598547.</li>
<li>Kuderer NM, Choueiri TK, et al. Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <em><strong>Lancet</strong></em>. 2020 Jun 20;395(10241):1907-1918. PMID: 32473681; PMCID: PMC7255743.</li>
<li><strong>Verma A</strong>, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R. Biological basis for efficacy of activing receptor ligand traps in myelodysplastic syndromes. <strong>J Clin Invest.</strong> 2020 Feb 3;130(2):582-589. doi: 10.1172/JCI133678. Review. PMID: 31961337</li>
<li>Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, D&iacute;ez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, G&ouml;tze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellstr&ouml;m-Lindberg E, Zeidan AM, Ad&egrave;s L, <strong>Verma A</strong>, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. <strong>N Engl J Med.</strong> 2020 Jan 9;382(2):140-151. PMID: 31914241</li>
<li>Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,&nbsp; Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,&nbsp;&nbsp;<strong>Verma A*.</strong>&nbsp;Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts&nbsp;<strong>Elife,</strong>&nbsp;Oct 30;8, 2019, (In Press)* Equal Contribution&nbsp;PMID: 31663852</li>
<li>Santini V, Valc&aacute;rcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B,&nbsp;<strong>Verma A</strong>.&nbsp;Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.&nbsp;<strong>Clin Cancer Res</strong>. 2019 Sep 3. PMID: 31481511</li>
<li>Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*,&nbsp;<strong>Verma A</strong>*, Starczynowski D*<br />
U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies.&nbsp;<strong>Nature Cell Bio</strong>&nbsp;2019&nbsp;May;21(5):640-650&nbsp;* Equal Contribution&nbsp;</li>
<li>Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C,&nbsp;<strong>Verma A</strong>,* Wickrema A*<br />
Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis <strong>Cancer Discovery</strong>&nbsp;2019 Jun;9(6):778-795&nbsp;* Equal Contribution</li>
<li>Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,&nbsp; Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,&nbsp;&nbsp;<strong>Verma A*.</strong>&nbsp;Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts&nbsp;<strong>Elife,</strong>&nbsp;Oct 30;8, 2019, (In Press)* Equal Contribution&nbsp;PMID: 31663852</li>
<li>Santini V, Valc&aacute;rcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B,&nbsp;<strong>Verma A</strong>.&nbsp;Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.&nbsp;<strong>Clin Cancer Res</strong>. 2019 Sep 3. PMID: 31481511</li>
<li>Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*,&nbsp;<strong>Verma A</strong>*, Starczynowski D*<br />
U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies.&nbsp;<strong>Nature Cell Bio</strong>&nbsp;2019 May;21(5):640-650&nbsp;* Equal Contribution&nbsp;</li>
<li>Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C,&nbsp;<strong>Verma A</strong>,* Wickrema A*<br />
Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis<br />
<strong>Cancer Discovery</strong>&nbsp;2019 Jun;9(6):778-795&nbsp;* Equal Contribution</li>
<li>Chen J, Kao Y, Sun D, Todorova T, Reynolds D, Narayanagari SR, Montagna C, Will B,&nbsp;<strong>Verma A</strong>*, Steidl U*Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level&nbsp;<strong>Nature Medicine</strong>&nbsp;2018,&nbsp;Jan;25(1):103-110&nbsp;* Equal Contribution</li>
<li>Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya, S. Lopez, R. Pradhan, K. Giricz, O. Ravipati, G. Wong, L. F. Cole, S. Bhagat, T. D. Feld, J. Dhar, Y. Bartenstein, M. Thiruthuvanathan, V. J.&nbsp; Wickrema, A. Ye, B. H. Frank, D. A. Pellagatti, A. Boultwood, J. Zhou, T. Kim, Y. MacLeod, A. R. Epling-Burnette, P. K. Ye, M. McCoon, P. Woessner, R. Steidl, U. Will, B.&nbsp;<strong>Verma, A.&nbsp;</strong>Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.&nbsp;<strong>J Clin Invest</strong>. 2018 Sep 25. PMID: 30252677</li>
<li>Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S,&nbsp;<strong>Verma A*</strong>, Ye BH*, Janakiram M.* North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.&nbsp;<strong>Blood.</strong>&nbsp;2018 Aug 13. PMID: 30104217 * Equal Contribution</li>
<li>Landgren O*, Zeig-Owens R*, Giricz O*, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl S, Pradhan K, Hall C, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP,&nbsp;<strong>Verma A*</strong>, Prezant DJ* Multiple Myeloma and Its Precursor Disease among Firefighters Exposed to the World Trade Center Disaster&nbsp;<strong>JAMA Onc</strong>, 2018 Jun 1;4(6):821-827. PMID: 29710195 &nbsp;* Equal Contribution</li>
<li>Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB,&nbsp;<strong>Verma A</strong>, Steidl U, Will B. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.&nbsp;<strong>Sci Transl Med</strong>. 2018 Sep 12;10(458). PMID: 30209246</li>
<li>Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA,&nbsp;<strong>Verma AK&nbsp;</strong>The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.&nbsp;<strong>JCI Insight</strong>. 2018 Jul 25;3(14). PMID: 30046005</li>
<li>Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA,&nbsp;<strong>Verma A</strong>, Steidl U. Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia.&nbsp;<strong>Sci Transl Med</strong>.&nbsp;2018, Apr 11;10(436). PMID: 29643228</li>
<li>Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debr&eacute; I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E,&nbsp;<strong>Verma A</strong>, Gritsman K, Steidl U.&nbsp; IL1RAP potentiates multiple oncogenic signaling pathways in AML.&nbsp;<strong>J Exp Med.</strong>&nbsp;2018 Jun 4;215(6):1709-1727 PMID: 29773641</li>
<li>Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways,&rdquo; &nbsp;<strong>Genome Res</strong>, 2017, Oct 6. PMID: 28986391</li>
<li>Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes M, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM,&nbsp; Mukherjee SM, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Wnt/&szlig;-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome,&rdquo;&nbsp;<strong>Cancer Research</strong>&nbsp;Jul, 2017, PMID: 28684528</li>
<li>Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD,&nbsp;<strong>Verma A</strong>, Steidl U, Gavathiotis E. Direct &ldquo;Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia,&rdquo;&nbsp;&nbsp;<strong>Cancer Cell</strong>&nbsp;2017 Oct 9.PMID: 29017059&nbsp;</li>
<li>Antony-Debr&eacute; I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E,&nbsp;<strong>Verma A</strong>, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U., &ldquo;Pharmacological inhibition of the transcription factor PU.1 in leukemia,&rdquo; &nbsp;<strong>J Clin Invest</strong>&nbsp;2017 Oct 30, PMID: 29083320</li>
<li>Yue L, Bartenstein M, Zhao W, Ho W, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ,&nbsp;<strong>Verma A*,</strong>&nbsp;Epling-Burnette PK* (*Co-Corresponding), &ldquo;Efficacy of ALK5 Inhibition in Myelofibrosis.&rdquo;&nbsp;&nbsp;&nbsp;<strong>JCI Insight&nbsp;</strong>(In Press)</li>
<li>Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, Yu Y, Ko YA, Izquierdo MC, Park ASD, Vallumsetla N, Laurence R, Lopez R, Suzuki M, Pullman J, Kaner J, Gartrell B, Hakimi AA, Greally JM, Patel B, Benhadji K, Pradhan K,&nbsp;<strong>Verma A*,</strong>&nbsp;Susztak K* (*Co-Corresponding), &ldquo;Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer .&rdquo; &nbsp;<strong>JBC&nbsp;</strong>2016, Dec 1. PMID: 2790905</li>
<li>Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S , Bhagat T, Bhattacharyya S, Assal A, Shastri A,&nbsp; Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M`, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U,&nbsp;<strong>Verma A,</strong>&nbsp; &ldquo;Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia.&rdquo;&nbsp;&nbsp;<strong>Cancer Res&nbsp;</strong>2016 Jun 10. PMID: 27287719</li>
<li>Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I,&nbsp; Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski J, Braunschweig I,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;High Prevalence and Allele Burden Independent Prognostic Importance of p53 Mutations in an Inner-City MDS/AML Cohort,&rdquo; &nbsp;<strong>Leukemia&nbsp;</strong>2016 Apr 29. PMID: 27125205</li>
<li>Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ,&nbsp;<strong>Verma A,</strong>&nbsp;Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG. &ldquo;MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.&rdquo;&nbsp;&nbsp;<strong>Nat Commun.</strong>&nbsp;2016 Feb 22;7:10739. PMID: 26898884</li>
<li>Platzbecker U, Wong RS,&nbsp;<strong>Verma A,</strong>&nbsp;Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, G&ouml;tze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A., &ldquo;Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.&rdquo;&nbsp;&nbsp;<strong>Lancet Haematol.</strong>&nbsp;2015 Oct;2(10):e417-26. PMID: 26686043</li>
<li>Sundaravel S, Duggan R, Bhagat TD, Ebenezer D, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Anastasi J, McGraw K, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau M, Steidl U, List A, Evans T*,&nbsp;<strong>Verma A</strong>*, Wickrema A*. (*Co-Corresponding),&nbsp; &ldquo;Reduced DOCK4 Expression Leads to Erythroid Dysplasia in Myelodysplastic Syndromes.&rdquo;&nbsp;&nbsp;<strong>PNAS</strong>&nbsp;2015; Nov 17;112(46): PMID: 26578796</li>
<li>Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.&rsquo;&nbsp;<strong>Nature Chem Biol</strong>. 2015 Oct 5. PMID: 26436839</li>
<li>PAK1 Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015 Jul 13. PMID: 26170031</li>
<li>Cabrero M, Yu Y,&nbsp;<strong>Verma A,</strong>&nbsp;Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y, &ldquo;Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.&rdquo;&nbsp;<strong>Br J Haematol.</strong>&nbsp;2015 Jun 24. PMID: 26105212</li>
<li>Vardabasso C, Gaspar-Maia A, Hasson D, P&uuml;nzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B,&nbsp;<strong>Verma A,</strong>&nbsp;Mann M, Hernando E, Hake SB, Bernstein E, &ldquo;Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.&rdquo;&nbsp;<strong>Mol Cell.</strong>&nbsp;2015 Jun 3. PMID: 26051178</li>
<li>Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG,&nbsp;<strong>Verma AK,</strong>&nbsp;Platanias LC, &ldquo;Human Schlafen 5 (SLFN5) is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma&nbsp; Cells.&rdquo;&nbsp;<strong>Mol Cell Biol.</strong>&nbsp;2015 May 26. PMID: 26012550</li>
<li>Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN,&nbsp;<strong>Verma A,</strong>&nbsp;Platanias LC, &ldquo;Central Role of ULK1 in Type I Interferon Signaling.&rdquo;&nbsp;<strong>Cell Reports</strong>&nbsp;2015, Apr 28;11(4):605-17. PMID: 25892232</li>
<li>Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S,&nbsp;<strong>Verma A,</strong>&nbsp;Jaenisch R, Aifantis I, &ldquo;TET1 is a tumor suppressor of hematopoietic malignancy.&rdquo;&nbsp;<strong>Nat Immunol.</strong>&nbsp;2015 Apr 13. PMID: 25867473</li>
<li>Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will W, Wei S, Steidl U*,&nbsp;<strong>Verma A*,&nbsp;</strong>&nbsp; *co-corresponding authors, &ldquo;IL8-CXCR2 pathway inhibition as a novel therapeutic strategy against MDS and AML stem cells.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015, Mar 25. PMID: 25810490&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, J&auml;dersten M, Dolatshad H,&nbsp;<strong>Verma A,</strong>&nbsp;Cross NC, Vyas P, Killick S, Hellstr&ouml;m-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J, &ldquo;Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic Syndromes.&rdquo;&nbsp;<strong>Nat Commun.</strong>&nbsp;2015 Jan 9;6:5901. PMID: 25574665&nbsp;</li>
<li>Caescu CI, Guo X, Tesfa L, Bhagat TD,&nbsp;<strong>Verma A,</strong>&nbsp;Zheng D, Stanley ER, &ldquo;Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015 Jan 8. PMID: 25573988</li>
<li>Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;Minimal reduction of PU.1 is sufficient to induce a preleukemic state and promote development of acute myeloid leukemia.&rdquo;&nbsp;<strong>Nature Medicine,</strong>&nbsp;2015 (In Print)</li>
<li>Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Targeting chemokine pathways in esophageal adenocarcinoma.&rdquo;&nbsp;<strong>Cell Cycle.</strong>&nbsp;2014 Nov 1;13(21):3320-7. PMID: 25485576</li>
<li>Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival.&rdquo;&nbsp;<strong>Clin Cancer Res.</strong>&nbsp;2014 Jun 10. PMID: 24916699</li>
<li>Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger R, Cohn S, Nanduri J,&nbsp;<strong>Verma A,</strong>&nbsp;Prabhakar N, Godley LA, &ldquo;TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.&rdquo;&nbsp;<strong>Cell Rep.</strong>&nbsp;2014 May 14. PMID: 24835990</li>
<li>Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J,&nbsp;<strong>Verma AK,</strong>&nbsp;Pellagatti A, Boultwood J, List AF, Williams DA, Ji P., &ldquo;Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) myelodysplastic syndromes.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2014 Jun 2. PMID: 24891322</li>
<li>Tamari R,&nbsp; Schinke C, Bhagat T, Roth M, Braunschweig I,&nbsp; Will B,&nbsp; Steidl U,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.&rdquo;&nbsp;<strong>Leuk Lymphoma,</strong>&nbsp;2014 Dec;55(12):2901-6.PMID: 24650011</li>
<li>Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine RL, Melnick A,&nbsp;<strong>Verma A*,</strong>&nbsp;Steidl U, *Co-Corresponding, &ldquo;A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia.&rdquo;&nbsp;<strong>Journal of Clinical Investigation</strong>&nbsp;2014 Feb 3 PMID: 24487588</li>
<li>Kuo P, Leshchenko V, Fazzari M, Gellen T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh K, Goy A, Yang D, Chan W, Kahl B,&nbsp;<strong>Verma A,</strong>&nbsp;Gascoyne R, Kimby E, Sander B, Ye BH, Melnick A, Perumal D, He T, Parekh S, &ldquo;High resolution Chromatin Immunoprecipitation (ChIP) sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma.&rdquo;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oncogene,</strong>&nbsp;2014 Mar 31 PMID: 24681958</li>
<li>Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, G&oacute;mez-Segu&iacute; I,&nbsp;<strong>Verma AK,</strong>&nbsp;McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP, &ldquo;Recurrent genetic defects on chromosome 7q in myeloid neoplasms.&rdquo;<strong>Leukemia</strong>&nbsp;2014 Jan 16. PMID: 24429498</li>
<li>Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, Grossman R, Raumann B,&nbsp;<strong>Verma A,</strong>&nbsp;He C, Levine RL, Lavelle D, Lahn BT, Wickrema A, Godley LA, &ldquo;Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis.&rdquo;&nbsp;<strong>Cell Reports</strong>&nbsp;2013 Dec 24 PMID: 24373966</li>
<li>Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, Fazzari M,&nbsp;<strong>Verma A,</strong>&nbsp;Zheng D, Greally JM, Susztak K, &ldquo;Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development.&rdquo;&nbsp;<strong>Genome Biol.</strong>&nbsp;2013 Oct 7;14(10):R108. PMID: 24098934</li>
<li>Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis AAN, Perry J, Malcovati L, Giovanni M, Porta D, J&auml;dersten M,&nbsp;&nbsp;<strong>Verma A,</strong>&nbsp;McDonald E, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J, &ldquo;Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.&rdquo;&nbsp;<strong>JCO</strong>&nbsp;2013 Oct 1;31(28):3557-64. PMID: 24002510</li>
<li>Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S,&nbsp;<strong>Verma AK,&nbsp;</strong>&nbsp;&ldquo;Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.&rdquo;&nbsp;&nbsp;<strong>Am J Hematol.</strong>&nbsp;2013 Nov;88(11):E245-9. PMID: 23828763</li>
<li>Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich Roland W, Khashab M, Singh VK, Shin EJ, Yang X, Verma&nbsp;<strong>A,</strong>&nbsp;Meltzer SJ, Mori Y, &ldquo;Long Noncoding RNA HNF1A-AS1 Regulates Proliferation and Migration in Esophageal Adenocarcinoma Cells.&rdquo;&nbsp;<strong>Gut</strong>&nbsp;2013 Sep 2. PMID: 24000294&nbsp;</li>
<li>Bajpai M, Kessel R, Bhagat T, Nischal S, Yu Y,&nbsp;<strong>Verma A*,</strong>&nbsp;Das K, *Co-Corresponding,&nbsp; &ldquo;High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells.&rdquo;&nbsp;<strong>Genes Chromosome Cancer</strong>&nbsp;2013 Oct 3. PMID: 24123713</li>
<li>Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A,&nbsp;<strong>Verma A,</strong>&nbsp;Fish EN, Platanias LC, &ldquo;Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors.&rdquo;&nbsp;&nbsp;<strong>JBC,</strong>&nbsp;2013 Aug 16;288(33):23814-22 PMID: 23814052</li>
<li>Bhattacharyya, Si; Yu, Y; Suzuki, M; Campbell, N; Mazdo, J; Vasantkumar, A; Bhagat, T; Nischal, S; Christopeit, M; Parekh, S; Steidl, U; Godley, L; Maitra, A; Greally, J;&nbsp;<strong>Verma, A;&nbsp;</strong>&nbsp;&ldquo;Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.&rdquo;&nbsp;<strong>Nucleic Acid Res</strong>&nbsp;2013&nbsp; Sep;41(16):e157 PMID: 23861445</li>
<li>Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD,&nbsp;<strong>Verma A,</strong>&nbsp;Figueroa ME, Melnick A, Roth M, Steidl U, &ldquo;Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.&rdquo;&nbsp;<strong>Nat Immunol.</strong>&nbsp;2013 May;14(5):437-45. PMID: 23563689</li>
<li>Bhagat T, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A , Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;miR-21 mediates hematopoietic suppression in MDS by activating TGF-bsignaling.&rdquo;&nbsp;<strong>Blood</strong>&nbsp;2013, Apr 11;121(15):2875-81. PMID: 23390194</li>
<li>Yu Y, Mo Y, Liu H, Bhattacharyya S, Ebenezer D, Sundaravel S, Caces B, Ulaszek J, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, Suzuki M, Steidl U, Godley L, Skoultchi A, Greally J, Wickrema A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;High resolution methylome analysis reveals widespread hypomethylation during human erythroid differentiation.&rdquo;&nbsp;<strong>JBC</strong>&nbsp;2013 Mar 29;288(13):8805-14. PMID: 23306203</li>
<li>Heuck C, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J,<strong>&nbsp;Verma A*,</strong>&nbsp;Singhal S,* Co-Corresponding, &ldquo;Myeloma is characterized by stage specific alterations in DNA methylation that occur early during myelomagenesis.&rdquo; &nbsp;<strong>Journal of Immunology</strong>&nbsp;2013 Mar 15;190(6):2966-75. PMID: 23408834</li>
<li>Wu W, Bhagat T, Yang X, Song J, Cheng Y, Agarwal R, Abraham J, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Eng C, Greally J,&nbsp;<strong>Verma A*,</strong>&nbsp;Meltzer SJ*, Co-Corresponding, &ldquo;Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett&rsquo;s Esophagus and Esophageal Adenocarcinoma.&rdquo;&nbsp;<strong>Gastroenterology</strong>&nbsp;2013 May;144(5):956-966. PMID: 23333711</li>
<li>Nischal S, Bhattacharyya S, Christopeit N, Yu Y, Zhou L, Bhagat T, Sohal S, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.&rdquo;&nbsp;<strong>Cancer Res,</strong>&nbsp;2012 Dec 27. PMID: 23066032</li>
<li>Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C,Tamari R, Yu Y, Bhagat T,&nbsp; Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.&rdquo;&nbsp;<strong>Blood</strong>&nbsp;2012; 120(10):2076-86. PMID: 22753872</li>
<li>Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R,&nbsp;<strong>Verma A,</strong>&nbsp;Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF, &ldquo;Randomized, dose-escalation study of the p38&alpha; MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.&rdquo;&nbsp;<strong>Leukemia.</strong>&nbsp;2012 Sep 11. PMID: 23032694</li>
<li>Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2012 Aug 9;120(6):1290-8. PMID: 22723552</li>
<li>Jerez A, Sugimoto Y, Makishima H,&nbsp;<strong>Verma A,</strong>&nbsp;Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP,&nbsp; &ldquo;Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.&rdquo;&nbsp;&nbsp;&nbsp;<strong>Blood.</strong>&nbsp;2012 Jun 21;119(25):6109-17. PMID: 22553315</li>
<li>Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2012 May 24. PMID: 22627766</li>
<li>Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U,&nbsp;<strong>Verma A.,</strong>&nbsp;&ldquo;Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.&rdquo;&nbsp;<strong>Leuk Lymphoma</strong>.2012 Apr 18.&nbsp; PMID: 22448921</li>
<li>Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL,<strong>&nbsp;Verma A,</strong>&nbsp;Maciejewski JP, McDevitt MA, Moliterno AR, &ldquo;Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.&rdquo;&nbsp;&nbsp;&nbsp;<strong>Haematologica.</strong>&nbsp;2011 Oct;96(10):1462-9. Epub 2011 Jun 28. PMID: 21712540</li>
<li>Sharma B, Altman JK, Goussetis DJ,&nbsp;<strong>Verma AK,</strong>&nbsp;Platanias LC, &ldquo;Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Aug 5;286(31):27506-14. Epub 2011 Jun 9. PMID:1659535</li>
<li>Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kanbhampati S, Parmar S, Nischal S, Heuck C, Suzuki M, Friedman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Aberrant epigenetic and genetic marks are seen in myelodysplastic leucocytes and reveal DOCK4 as a candidate pathogenic gene on chr7q.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Apr 30. PMID: 21532034&nbsp;</li>
<li>Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y, Montagna C, Montgomery E, Canto M, Dunbar K, Wang J, Roa J, Mo Y, Bhagat T, Ramesh K, Cannizzaro L, Mollenhauer J, Thompson R, Suzuki M, Meltzer S, Melnick A, Greally JM, Maitra A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.&rdquo;&nbsp;<strong>PLOS Genetics</strong>&nbsp;2011 Mar;7(3) PMID: 21483804</li>
<li>L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M Fazzari, D Sohal, C Heuck, K Gundabolu, C Ng, Y Mo, W Shen, A Wickrema, G Kong, E Friedman, L Sokol,&nbsp; G Mantzaris, A Pellagatti , J Boultwood, LC Platanias, U Steidl, L Yan, JM Yingling, MM Lahn, A List, M Bitzer and&nbsp;<strong>A Verma,</strong>&nbsp;&ldquo;Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.&rdquo;&nbsp;<strong>Cancer Research</strong>&nbsp;2011 Feb 1;71(3):955-63.PMID: 21189329</li>
<li>Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R,<strong>&nbsp;Verma AK,</strong>&nbsp;Fish EN, Platanias LC, &ldquo;Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.&rdquo;&nbsp;&nbsp;<br />
<strong>J Biol Chem.</strong>&nbsp;2011 Feb 25;286(8):6017-26.PMID: 21149447</li>
<li>Kroczynska B, Joshi S, Eklund EA,&nbsp;<strong>Verma A,</strong>&nbsp;Kotenko SV, Fish EN, Platanias LC, &ldquo;Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFN&lambda; signaling.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Jan 14;286(2):1147-56. Epub 2010 Nov 12.</li>
<li>Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC,&nbsp;<strong>Verma A*,</strong>&nbsp;Das B, &ldquo;Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.&rdquo;&nbsp;<br />
<strong>Leuk Lymphoma.</strong>&nbsp;2010 Jun;51(6):1108-14. PMID: 20536349</li>
<li>Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y,&nbsp;<strong>Verma A,</strong>&nbsp;Theil KS, McDevitt MA, Maciejewski JP, &ldquo;Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.&rdquo;&nbsp;<strong>Genes Chromosomes Cancer.</strong>&nbsp;2010 Apr;49(4):390-9. PMID: 20095039</li>
<li>Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, J&auml;dersten M,&nbsp;<strong>Verma A,</strong>&nbsp;Norbury C Hellstr&ouml;m-Lindberg E, Wainscoat JS, Boultwood J, &ldquo;Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.&rdquo;&nbsp;<strong>Leukemia.</strong>&nbsp;2010 Apr;24(4):756-64. PMID: 20220779</li>
<li>Einstein F, Thompson RF, Bhagat TD, Fazzari MJ,&nbsp;<strong>Verma A,</strong>&nbsp;Barzilai N, Greally JM, &ldquo;Cytosine methylation dysregulation in neonates following intrauterine growth restriction.&rdquo;&nbsp;<strong>PLoS One.</strong>&nbsp;2010 Jan 26;5(1):e8887 PMID: 20126273</li>
<li>Oda M., Glass J.L., Thompson R.F., Mo Y., Olivier E., Figueroa M.E., Selzer R.R., Richmond T.A., Zhang X., Dannenberg L., Green R., Melnick A., Hatchwell E., Bouhassira E.,&nbsp;<strong>Verma A.,</strong>&nbsp;Suzuki M., Greally J.M., &ldquo;High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers.&rdquo;&nbsp;<strong>Nucleic Acids Res.</strong>&nbsp;2009 Jul;37(12):3829-39.&nbsp;&nbsp; PMID: 19386619</li>
<li>Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally JM,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.&rdquo;&nbsp;<strong>PLOS One</strong>&nbsp;2008 Aug 13;3(8):e2965&nbsp;&nbsp;&nbsp; PMID: 18698424</li>
<li>Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, Hayman J, Chubak A,&nbsp;&nbsp; Mo Y, Bhagat T, Das B, Haghnazari E, Navas T, Parmar S, Kambhampati S, Pellagati A,&nbsp; Braunchweig I, Zhang YE, Wickrema A, Boultwood J, Platanias LC, Higgins LS, List A, Bitzer M,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of Transforming Growth Factor beta receptor I kinase can stimulate hematopoiesis in Myelodysplasia.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Blood</strong>&nbsp;2008 Oct 15;112(8):3434-43&nbsp; PMID: 18474728</li>
<li>Navas T, Zhou L, Estes M, Haghnazari E, Nguyen A, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins L, Platanias LC, List A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of p38a MAPK disrupts the pathological loop of proinflammatory factor production in the Myelodysplastic Syndrome bone marrow microenvironment.&rdquo; &nbsp;<strong>Leukemia and Lymphoma</strong>&nbsp;2008 Oct;49(10):1963-75</li>
<li>Zhou L, Opalinska J,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.&rdquo;&nbsp;<strong>Cell Cycle&nbsp;</strong>2007<strong>,</strong>&nbsp;1;6(5):534</li>
<li>Navas T, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P,&nbsp;Parmar S, Haghnazari E, Zhou L, Collins RC, Kerr I, Nguyen A, Xu Y, Platanias LC, List AA, Higgins LS,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.&rdquo;&nbsp;<strong>Blood&nbsp;</strong>2006, 15;108(13):4170-7</li>
<li><strong>Verma A,</strong>&nbsp;and List A, &ldquo;Cytokine Targets in Myelodysplastic syndromes.&rdquo;&nbsp;<strong>Current Hematology Reports</strong>&nbsp;2005 Nov;4(6):429-35</li>
<li>Deonarain R,&nbsp;<strong>Verma A,</strong>&nbsp;Porter AC, Gewert DR, Platanias LC, Fish EN, &ldquo;Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.&rdquo;&nbsp;<strong>Proc Natl Acad Sci USA.</strong>&nbsp;2003 Nov 11;100(23):13453-8</li>
<li><strong>Verma A,</strong>&nbsp;Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, Van Besien K, &ldquo;Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.&rdquo;&nbsp;&nbsp;<strong>Bone Marrow Transplant.</strong>&nbsp;2003 May;31(9):813-6.</li>
<li><strong>Verma A.,</strong>&nbsp;Mohindru M., Deb D., Sassano A., Kambhampati S., Minucci S., Ravandi F., Kovakanalu D, Platanias L., &ldquo;Activation of the Rac1 and p38 MAP kinase pathway in response to Arsenic trioxide.&rdquo;&nbsp;&nbsp;<strong>Journal of Biological Chemistry</strong>&nbsp;22;277(47):44988-95</li>
<li><strong>Verma A,</strong>&nbsp;Sassano A, Deb D, Wickrema, A., VanBesien K., and Platanias L., &ldquo;Blockade of p38 MAP kinase reverses cytokine mediated inhibition in aplastic anemia.&rdquo;&nbsp;<strong>Journal of Immunology</strong>&nbsp;2002, 168 (12) (Cutting edge section)</li>
<li><strong>Verma A,</strong>&nbsp;Deb D.K., Sassano A., Uddine S., Wickrema A., Varga and Platanias LC, &ldquo;Activation of the p38 mitogen activated protein kinase mediates suppressive effects of Type I interferons and transforming growth factor-b on normal hematopoiesis.&rdquo;&nbsp;<strong>Journal of Biological Chemistry</strong>&nbsp;2002, 277(10):7726-35</li>
<li>Devine S, Hoffman R,&nbsp;<strong>Verma A,</strong>&nbsp;Shah R, Bradlow B, Stock W and Van Besien K, &ldquo;Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis.&rdquo;<strong>&nbsp;Blood&nbsp;</strong>&nbsp;2002, 99(6):2255-8</li>
</ol>
<p><strong>Review articles</strong></p>
<ol start="1" type="1">
<li>Li W, Morrone K, Kambhampati S, Will B, Steidl U,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.&rdquo;&nbsp;<strong>Leukemia,&nbsp;</strong>2015 (In Press)</li>
<li>Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K,&nbsp;<strong>Verma A.,&nbsp;</strong>"Role of DNA methylation in renal cell carcinoma."&nbsp;<strong>J Hematol Oncol.</strong>&nbsp;2015 Jul 22;8(1):88. PMID: 26198328</li>
<li><strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.&rdquo;&nbsp;<br />
<strong>Nat Med.</strong>&nbsp;2015;21:113-4.&nbsp; PMID: 25654599</li>
<li>Ga&ntilde;&aacute;n-G&oacute;mez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, Garcia-Manero G, "Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes."&nbsp;<strong>Leukemia.</strong>&nbsp;2015 Mar 12. PMID: 25761935</li>
<li>Shenoy N, Vallumsetla N,&nbsp; Rachmilewitz E,&nbsp;<strong>Verma A,</strong>&nbsp;Ginzburg Y., "Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome."&nbsp;<strong>Blood,</strong>&nbsp;2014 Aug 7;124(6):873-81. PMID: 24923296</li>
<li>Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P,&nbsp;<strong>Verma A,</strong>&nbsp;Ray SK,&nbsp;&nbsp;&nbsp; Evans T.,&nbsp; "Retinoic acid signaling pathways in development and diseases."<br />
<strong>Bioorg Med Chem.</strong>&nbsp;2014 Jan 15;22(2):673-83. PMID: 24393720</li>
<li>Elias HK, Schinke C, Bhattacharyya S, Will B*,&nbsp;<strong>Verma A*,&nbsp;</strong>&nbsp;Steidl U* *CoCorresponding,&nbsp;&nbsp;&nbsp; &ldquo;Stem cell origin of myelodysplastic syndromes.&rdquo;&nbsp;<strong>Oncogene</strong>&nbsp;2013 Dec 16. PMID: 24336326</li>
<li>Pathak S, Roth M,&nbsp;<strong>Verma A*,</strong>&nbsp;Steidl U*.&nbsp; *CoCorresponding,&nbsp;&nbsp;&nbsp; &ldquo;Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.&rdquo;<br />
<strong>Expert Opin Drug Metab Toxicol.</strong>&nbsp;2013 Dec;9(12):1667-75. PMID: 24215532</li>
<li>Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y,&nbsp;<strong>Verma AK,&nbsp;&nbsp;</strong>&ldquo;Linked-in: design and efficacy of antibody drug conjugates in oncology.&rdquo;&nbsp;<strong>Oncotarget</strong>&nbsp;2013 Mar;4(3):397-412. PMID: 23651630</li>
<li>Khan H, Vale C, Bhagat T,&nbsp;<strong>Verma A.,&nbsp;&nbsp;&nbsp;</strong>&ldquo;Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.&rdquo;<br />
<strong>Semin Hematol.</strong>&nbsp;2013 Jan;50(1):16-37. PMID: 23507481</li>
<li>Elias H,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia.&rdquo;<br />
<strong>Leuk Lymphoma.</strong>&nbsp;2012 Dec;53(12):2337-8. PMID: 22897726</li>
<li>Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C,&nbsp;<strong>Verma A.,&nbsp;&nbsp;</strong>&ldquo;Alterations in the ribosomal machinery in cancer and hematologic disorders.&rdquo;&nbsp;<strong>J Hematol Oncol.</strong>&nbsp;2012 Jun 18;5:32. PMID: 22709827</li>
<li>Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A,&nbsp;<strong>Verma A.,&nbsp;&nbsp;</strong>&ldquo;Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.&rdquo;&nbsp;<strong>Int J Clin Exp Pathol.</strong>&nbsp;2012;5(5):382-96. PMID: 22808291</li>
<li>Sharma A,&nbsp; Heuck C, Fazzari M, Mehta J, Singhal S, Greally JM,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;DNA methylation alterations seen in myeloma as a model of epigenetic changes in cancer.&rdquo;&nbsp;<strong>WIREs Systems Biology and Medicine</strong>&nbsp;2010 Nov-Dec;2(6):654-69. PMID: 20890963</li>
<li>Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally JM,&nbsp;<strong>Verma A,&nbsp; &ldquo;</strong>Aberrant DNA methylation in malignant melanoma.&rdquo;&nbsp;<strong>Melanoma Research</strong>&nbsp;2010, Aug; 20(4):253-65 PMID: 20418788</li>
<li>Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B,&nbsp;<strong>Verma A.,&nbsp;</strong>&ldquo;Mechanism of action of lenalidomide in hematological malignancies.&rdquo;<br />
<strong>J Hematol Oncol.</strong>&nbsp;2009 Aug 12;2:36</li>
<li>Opalinska J, Zhou L,&nbsp;<strong>Verma A.,&nbsp;</strong>&ldquo;A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL.&rdquo;&nbsp;<strong>Leukemia Research (Commentary)</strong>&nbsp;2007, 48(3):443</li>
<li>Isufi I, Seetharam M, Sohal D, Zhou L, Opalinska J, Pahanish P,&nbsp;<strong>Verma A., &ldquo;</strong>Transforming Growth Factor-beta Signaling in Normal and Malignant Hematopoiesis.&rdquo;&nbsp;<strong>Journal of Interferon and Cytokine Research</strong>&nbsp;2007, 27(7):543</li>
<li>Mohindru M,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;Engineered antibodies act as targeted therapies in cancer treatment.&rdquo;&nbsp;<strong>Indian Journal of Pediatrics,</strong>&nbsp;2005 Nov;72(11):943-7</li>
<li>Sassano A,&nbsp;<strong>Verma A,</strong>&nbsp;Platanias LC, "Mitogen-activated protein kinase pathways in interferon signaling."&nbsp;<strong>Methods Molecular Medicine,</strong>&nbsp;2005;116:135-50.</li>
<li>Mohindru M,&nbsp;<strong>Verma A,&nbsp;</strong>"Kinase inhibitors translate lab discoveries into exciting new cures for cancers."&nbsp;<strong>Indian Journal of Pediatrics,</strong>&nbsp;2004 Aug;71(8):713-8.</li>
<li><strong>Verma A,</strong>&nbsp;Kambhampati S, Parmar S, Platanias LC,&nbsp; &ldquo;Jak family of kinases in cancer.&rdquo;&nbsp;<strong>Cancer Metastasis Rev.</strong>&nbsp;2003 Dec;22(4):423-34.(rev)</li>
<li><strong>Verma A,</strong>&nbsp;and Platanias LC, &ldquo;Signaling via the interferon-a receptor in chronic myelogenous leukemia cells.&rdquo;&nbsp;<strong>Leukemia and Lymphoma&nbsp;</strong>&nbsp;2002, 44:703-709</li>
<li><strong>Verma A,</strong>&nbsp;and Stock W, &ldquo;Management of adult lymphoblastic leukemia: moving toward a risk-adapted approach.&rdquo;&nbsp;<strong>Current Opinion in Oncology,</strong>&nbsp;2001, 13:14-20</li>
<li><strong>Verma A,</strong>&nbsp;and Gupta YK,&nbsp; &ldquo;The search for a super oral rehydration solution (0RS).&rdquo;&nbsp;<strong>Drugs: News and Views,</strong>&nbsp;1995, 3(2):129-132.&nbsp;</li>
</ol>

EMR ID

4772

Biography

<p>Amit K. Verma, MD, is Interim Chair, Department of Oncology, Associate Director of Translational Science, Montefiore Einstein Comprehensive Cancer Center, Professor, Medical Oncology and Professor, Developmental & Molecular Biology, Albert Einstein College of Medicine.</p><p>Dr. Verma earned his Doctor of Medicine at the All India Institute of Medical Sciences in 1995 and finished his training in internal medicine, hematology oncology and stem cell transplantation at the University of Illinois and Northwestern University in 2003.</p><p>Dr. Verma conducts clinical studies for patients with MDS and leukemia and offers a variety of clinical trials for these patients. He conducts laboratory research aimed at discovering new treatments for myelodysplastic syndromes (MDS) and leukemias, and his research has shown that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways are overactivated in MDS. His work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. DR. Verma&rsquo;s research has shown that MDS and leukemias are caused by aberrant leukemic stem cells and has identified novel targets against MDS/AML stem cells that are being tested in various studies.</p><p>Dr. Verma is a scholar of the Leukemia and Lymphoma society, elected member of American society of clinical investigation and his research is funded by the NIH, Department of Defense, American Cancer Society, Edward P. Evans Foundation and various other private foundations.</p>

Is Open Scheduling

Off

Roberto Alejandro Sica

https://assets.montefioreeinstein.org/profiles/images/physphoto/Sica_Roberto_Alejandro_MD_420x504.jpg

First Name

Roberto Alejandro

Last Name

Sica

NPI

1316133648

Faculty ID

15943

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sica&rsquo;s clinical focus has been on chimeric antigen receptor (CAR) T-cell therapies, immunotherapies and allogeneic stem cell transplantation, central nervous system (CNS) lymphomas and HIV, ATLL and gene therapy for malignant and nonmalignant hematologic disorders.

Research Focus

Dr. Sica&rsquo;s research focuses on novel cellular therapies, allogeneic bone marrow transplantation for malignant and nonmalignant hematologic disorders, and combination immunotherapy and cancer vaccine.

Elsevier Profile

EMR ID

15901

Biography

<p>Roberto Alejandro Sica, MD, is an Attending Physician at Montefiore and an Assistant Professor of Medicine at our Albert Einstein College of Medicine. Since joining the Montefiore team, Dr. Sica&rsquo;s clinical focus has been on chimeric antigen receptor (CAR) T-cell therapies, immunotherapies and allogeneic stem cell transplantation, central nervous system (CNS) lymphomas and HIV, ATLL and gene therapy for malignant and nonmalignant hematologic disorders. Dr. Sica is a member of the Bone Marrow Transplant team at Montefiore.</p><p>Dr. Sica attended the University of Buenos Aires School of Medicine, where he received his Medical Degree. During his time there, he also served as an instructor of immunology, virology, pharmacology, and physical diagnosis. Dr. Sica began his postgraduate training with a residency in Internal Medicine at the Carney Hospital/Tufts University School of Medicine in Boston. Following this, he completed a fellowship in Hematology/Oncology at the University of Illinois at Chicago, where he received the E. Donnall Thomas Achievement in Medicine Award for his academic performance and the Edward Jenner Innovation in Medicine Award in recognition of his innovative contributions to the design of clinical protocols and trials. Later, he completed a fellowship in Blood and Marrow Transplant and Cellular Therapies at Stanford University. At that institution, he performed research with Dr. Sally Arai on Hodgkin's lymphoma using the Stanford-pioneered GN-BVC regimen (Gemcitabine, Vinorelbine-BCNU. Etoposide and Cyclophosphamide) which resulted in decreased toxicity and improved overall survival in patients. His work has been published in various review journals and abstracts.</p><p>Dr. Sica&rsquo;s research focuses on novel cellular therapies, allogeneic bone marrow transplantation for malignant and nonmalignant hematologic disorders, and combination immunotherapy and cancer vaccine.</p><p>Dr. Sica is board certified in Internal Medicine, Hematology and Medical Oncology by the American Board of Internal Medicine.</p>

Is Open Scheduling

Off

Aditi Shastri

https://assets.montefioreeinstein.org/profiles/images/Shastri_Aditi_2x.jpg

First Name

Aditi

Last Name

Shastri

NPI

1568797058

Faculty ID

14819

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>I am a board certified hematologist and medical oncologist. I specialize in caring for patients with hematologic malignancies and specifically myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and aplastic anemia (AA).</p>
<p>I have a strong interest in exploring novel treatment approaches for myelodysplatic syndromes (MDS) and Acute Myeloid Leukemia (AML) after the failure of therapy with hypomethylating agents. I specifically focus on therapeutically targetting the transcription factor STAT3 in MDS and AML.</p>
<p>My research was previously funded through the NIH Paul Calabresi Career Development Award (K12) &amp; currently through the Leukemia Lymphoma Society (LLS)-TRP Award &amp; MDS Foundation Gilbert Bruce Smith Young Investigator Award.</p>
<p>My original research and reviews have been published in leading peer reviewed journals that include Blood, JCI, Nature Reviews Cancer &amp; Lancet Hematology.&nbsp; I have been an invited speaker at several conferences and forums nationally as well as internationally.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Lab Website Link

EMR ID

57152

Is Open Scheduling

Off

Mark A. Ramirez

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ramirez_Mark_MD.jpg

First Name

Mark

Last Name

Ramirez

NPI

1467494336

Faculty ID

3064

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3582

Is Open Scheduling

Off

Stuart Packer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0d90dcb0-3939-11ed-9b41-f32856b0701a.jpg

First Name

Stuart

Last Name

Packer

NPI

1124059621

Faculty ID

13484

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p>
<p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore&rsquo;s Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p>
<p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer, Clinical Cancer Research, British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer.

Elsevier Profile

EMR ID

5497

Biography

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p><p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore's Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p><p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer</em>, <em>Clinical Cancer Research</em>, <em>British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Is Open Scheduling

Off

Irina Murakhovskaya

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/4f602dc0-4e1f-11ee-8db1-bb4c384b05c4.jpg

First Name

Irina

Last Name

Murakhovskaya

NPI

1235180464

Faculty ID

13953

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Irina Murakhovskaya is an Assistant Professor of Medicine (Hematology). She completed a medical degree at Albert Einstein College of Medicine and residency and fellowship training at Montefiore Health System. Her clinical interests focus on monoclonal gammopathy, low-grade lymphoma, and hematologic issues in pregnancy.</p>
<p>Dr. Murakhovskaya is currently chairman of the fellowship Clinical Competency Committee and assistant course director for the Albert Einstein of Medicine Hematology Course.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4308

Is Open Scheduling

Off

Ioannis Mantzaris

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b67e5d80-3938-11ed-a06a-83625b154202.jpg

First Name

Ioannis

Last Name

Mantzaris

NPI

1871865519

Faculty ID

14586

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

57027

Is Open Scheduling

Off

Kenneth G. Liu

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/62a47410-3938-11ed-9b41-f32856b0701a.jpg

First Name

Kenneth

Last Name

Liu

NPI

1174840888

Faculty ID

15135

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

57009

Is Open Scheduling

Off

Kira Gritsman

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6b993220-5d55-11ef-92db-0be6da54f487.jpg

First Name

Kira

Last Name

Gritsman

NPI

1174598148

Faculty ID

14128

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>The Roles of Signaling Pathways in Adult Blood Development and Leukemia</strong></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">The Gritsman lab studies the signal transduction pathways that affect the early fate decisions of adult hematopoietic stem cells (HSCs) as they progress from an undifferentiated multipotent state to the generation of differentiated blood cells.&nbsp; When these early fate decisions go awry, this can lead to the formation of leukemia-initiating cells. We are interested in</span><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;how signaling pathways affect the self-renewal and differentiation of HSCs and malignant or pre-malignant stem cells in myeloid malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).</span></p>
<p><strong>Roles of the PI3 kinase isoforms in adult blood development</strong></p>
<p>PI3 kinase (PI3K) is a lipid kinase that is important for the regulation of metabolism, the cell cycle, apoptosis, and protein synthesis. &nbsp;In hematopoietic cells, there are four isoforms of the catalytic subunit of PI3K, each encoded by a separate gene. &nbsp;Emerging evidence suggests that these isoforms have unique functions in normal and cancer cells, but may substitute for each other in some contexts.&nbsp; We have generated a series of mouse knockout models that allow us to study the roles of each of these isoforms individually in adult hematopoiesis.&nbsp; For example, we have found that the p110alpha isoform is most important for red cell development, but is not required in normal blood stem cells. We have now also generated compound knockout mice to determine the redundant roles of the PI3K isoforms in blood development. &nbsp;We recently reported that PI3K isoforms play important redundant roles during the hematopoietic stress response, such as after chemotherapy. However, deletion of all 3 Class IA PI3K isoforms leads to a phenotype with impaired HSC differentiation, resembling myelodysplastic syndrome (MDS). We are studying how deletion of PI3K will impact normal HSC function, including self-renewal, proliferation, and differentiation along different blood lineages by affecting processes such as autophagy and epigenetic regulation in HSCs.</p>
<p><strong>Roles of the PI3 kinase isoforms in leukemia</strong></p>
<p>Acute myeloid leukemia (AML) is a genetically diverse disease, but activation of the PI3K pathway has been reported in up to 80% of cases.&nbsp; A subset of AML cell lines and AML patient samples respond to PI3K pathway inhibitors, but it is unclear how patients should be selected for potential response to these inhibitors. &nbsp;We found that RAS-mutated myeloid leukemias are particularly dependent on the p110alpha isoform of PI3K, and that pharmacologic inhibition of p110alpha can be used to treat both RAS-mutated cell lines and RAS-mutated leukemia in mice. Furthermore, we use cell lines, patient samples, and mouse models of leukemia to investigate the mechanisms of resistance to PI3K inhibition, with the goal of identifying new drug targets and designing new combination treatments for leukemia that incorporate PI3K inhibitors.</p>
<p><strong>RON Kinase in Myeloproliferative Neoplasms</strong></p>
<p>The myeloproliferative neoplasms (MPNs) are a group of diseases that are caused by kinase mutations in HSCs, which lead to uncontrolled proliferation of myeloid cells. The Philadelphia chromosome-negative MPNs are characterized by mutations in the JAK/STAT signaling pathway, and respond to JAK inhibitors, but resistance often develops. We recently discovered that the receptor Tyrosine kinase RON can physically interact with JAK2 in MPN cells, leading to potentiation of JAK/STAT signaling in resistant cells. Furthermore, we found that pharmacologic or genetic inactivation of RON can inhibit proliferation of MPN cells and re-sensitize resistant cells to JAK inhibitors.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;"><strong><span style="font-size: 10.5pt; font-family: Verdana, sans-serif; color: #201f1e;">Member of the Cancer Dormancy and Tumor Microenvironment Institute&nbsp;</span></strong></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">The Gritsman lab&rsquo;s research interests include the contributions of signaling pathways to leukemic and pre-leukemic stem cell dormancy in minimal residual disease, which includes mechanisms of immune evasion. Furthermore, the Gritsman lab is interested in the roles of inflammatory signaling pathways and of the local microenvironment in bone marrow fibrosis, and in the evolution of myeloid neoplasms from the pre-malignant to malignant state. Our major goals are to identify opportunities for therapeutic targeting to prevent the transition from the pre-leukemic state to leukemia, or to eliminate minimal residual disease to prevent relapse.</span></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><a name="_GoBack"></a><span style="font-size: 11pt; font-family: Arial, sans-serif;">Ames, K.,&nbsp;^&nbsp;Kaur,^&nbsp;I., Shi, Y., Tong, M., Sinclair, T., Hemmati, S., Glushakow-Smith, S.G., Tein,&nbsp;&nbsp;E., Gurska, L., Steidl, U., Dubin, R., Shan, J., Montagna, C., Pradhan, K., Verma, A., and&nbsp;<strong><u>Gritsman, K.</u></strong>, Deletion of PI3-Kinase Promotes Myelodysplasia Through Dysregulation of Autophagy in Hematopoietic Stem Cells,&nbsp;<strong><em>Science Advances</em></strong><em>&nbsp;2023.&nbsp;</em>doi:&nbsp;<a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.o…; target="_blank" rel="noopener"><span style="color: black; text-decoration: none;">10.1126/sciadv.ade8222</span></a><u>,&nbsp;</u>PMID:&nbsp;36812307</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><em><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></em></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Folgado Marco, V., Ames, K., Chuen, J.,&nbsp;<strong><u>Gritsman, K.</u></strong>&nbsp;&amp; Baker, N.,&nbsp;Haploinsufficiency of the essential gene&nbsp;<em>RpS12</em>&nbsp;causes defects in erythropoiesis and hematopoietic stem cell maintenance,&nbsp;<em>&nbsp;<strong>eLife</strong>&nbsp;</em>2023&nbsp;Jun 5;12:e69322. doi: 10.7554/eLife.69322.&nbsp;PMID:&nbsp;37272618</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gurska, L.M., Okabe, R., Schurer, A., Tong, M.M., Soto, M., Choi, D., Ames, K., Glushakow-Smith, S., Montoya, A., Tein, E., Miles, L.A., Cheng, H., Hankey-Giblin, P., Levine, R.L., Goel, S., Halmos, B., and&nbsp;<strong><u>Gritsman, K.</u></strong>&nbsp;Crizotinib has Preclinical Efficacy in Philadelphia-negative Myeloproliferative Neoplasms,&nbsp;<strong><em>Clinical Cancer Research</em></strong>&nbsp;2022&nbsp;Dec 20:CCR-22-1763. doi: 10.1158/1078-0432.CCR-22-1763. PMID:&nbsp;36537918</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gurska, L., Ames, K., and&nbsp;<strong><u>Gritsman, K</u></strong>, Signaling Pathways in Leukemic Stem Cells,&nbsp;</span><span style="font-size: 11pt; font-family: Arial, sans-serif; color: #333333; letter-spacing: 0.2pt; background-color: #fcfcfc;">In: Zhang H., Li S. (eds) Leukemia Stem Cells in Hematologic Malignancies.&nbsp;<strong>Advances in Experimental Medicine and Biology</strong>, vol 1143. Springer, Singapore</span><span style="font-size: 11pt; font-family: Arial, sans-serif;">, July 24, 2019, doi:&nbsp;<a href="https://doi.org/10.1007/978-981-13-7342-8_1"><span style="color: black; letter-spacing: 0.2pt; background-color: #fcfcfc; text-decoration: none;">https://doi.org/10.1007/978-981-13-7342-8_1</span></a><span style="letter-spacing: 0.2pt; background-color: #fcfcfc;">;&nbsp;</span>PMID:&nbsp;31338813, PMCID:&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7249489/&quot; target="_blank" rel="noopener"><span style="color: black; text-decoration: none;">PMC7249489</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Hemmati, S., Sinclair, T., Tong, M., Bartholdy, B., Okabe, R.O., Ames, K., Ostrodka, L., Haque, T., Kaur, I., Mills, T. S., Agarwal, A., Pietras, E.M., Zhao, J.J., Roberts, T.M., and&nbsp;<strong><u>Gritsman, K.</u></strong>, PI3 kinase alpha and delta promote hematopoietic stem cell activation,&nbsp;<strong><em>JCI Insight&nbsp;</em></strong>2019&nbsp;doi.org/10.1172/jci.insight.125832</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Mitchell, K., Barreyro, L., Todorova, T., Taylor, S., Antony-Debre, I., Narayanagari, S., Carvajal, L., Leite, J., Piperdi, Z., Pendurti, G., Mantzaris, I., Paietta, E., Verma, A.,&nbsp;<strong><u>Gritsman, K.,&nbsp;</u></strong>and Steidl, U. IL1RAP potentiates multiple oncogenic signaling pathways in AML,&nbsp;<strong><em>Journal of&nbsp;Experimental Medicine</em></strong><em>.&nbsp;</em>2018 May 17. doi: 10.1084/jem.20180147,&nbsp;PMID: 29773641</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Hemmati, S., Haque, T., and&nbsp;<strong><u>Gritsman, K</u>,&nbsp;</strong>Inflammatory Signaling Pathways in Pre-leukemic and Leukemic Stem Cells,&nbsp;<strong><em>Frontiers in Oncology</em></strong><em>&nbsp;</em>2017 Nov 13;7:265. doi: 10.3389/fonc.2017.00265</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Bhagat, T.D., Chen, S., Bartenstein, M., Barlowe, A.T., Von Ahrens, D., Choudhary, G.S., Tivnan, P., Amin, E., Marcondes, M., Sanders, M.A., Hoogenboezem, R.M., Kambhampati, S., Ramanchandra, N., Mantzaris, I., Sukrithan, V., Laurence, R., Lopez, R. Bhagat, P., Giricz, O., Sohal, D., Wickrema, A., Yeung, C.,&nbsp;<strong><u>Gritsman, K.,</u></strong>&nbsp;Aplan, P., Hochedlinger, K., Yu, Y., Pradhan, K., Zhang, J., Greally, J.M., Mukherjee, S., Pellagatti, A., Boultwood, J., Will, B., Steidl, U., Raaijmakers, M.H.G.P., Deeg, H.J., Kharas, M.G. and Verma, A. Epigenetically Aberrant Stroma in MDS Propagates Disease Via Wnt/b-Catenin Activation, 2017&nbsp;<strong><em>Cancer Research</em></strong>&nbsp;2017 Jul 6. pii: canres.0282.2017. doi: 10.1158/0008-5472</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Yuzugullu, H., Baitsch, L., Von, T., Steiner, A., Tong, H., Ni, J., Clayton, L., Bronson, R., Roberts, T.,&nbsp;<strong><u>Gritsman, K</u></strong><u>.</u>, and Zhao, J.J. A p110b-Rac signaling loop mediates Pten-loss-induced perturbation of hematopoiesis and leukemogenesis.&nbsp;<strong><em>Nature Communication</em></strong><em>s&nbsp;</em>October 7,2015, doi:10.1038/NCOMMS9501</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., Weigert, O., Kopp, N., Wu, S-C., Kim, S., Liu, H., Tivey, T., Christie, A.L.,&nbsp;<strong><u>Gritsman, K.</u></strong>,&nbsp; Gotlib, J., Deininger, M., Turley, S., Tyner, J., Marto, J., Weinstock, D.M., and Lane, A.A. Mutations in G-protein beta subunits promote transformation and kinase inhibitor resistance&nbsp;<strong><em>Nature Medicine</em></strong><em>&nbsp;</em>2015 (1):71-5.</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><strong><u><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gritsman, K</span></u></strong><strong><span style="font-size: 11pt; font-family: Arial, sans-serif;">.</span></strong><span style="font-size: 11pt; font-family: Arial, sans-serif;">, Yuzugullu, H., Von, T., Yan, H., Clayton, L., Fritsch, C., Maira, S.-M., Hollingworth, G., Choi, C., Khandan, T., Paktinat, M., Okabe, R.O., Roberts, T.M., and Zhao, J.J. &nbsp;Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha<strong>.&nbsp;<em>Journal of Clinical Investigation&nbsp;</em></strong>2014;124(4):1794&ndash;1809.&nbsp;http://www.jci.org/articles/view/69927</span></p&gt;
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Kharas, M.G. and&nbsp;<strong><u>Gritsman, K</u></strong>. Akt: A Double-Edged Sword for Hematopoietic Stem Cells.&nbsp;<strong><em>Cell Cycle</em>&nbsp;</strong>2010; Vol 9; Issue 7</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Kharas, M.G., Okabe, R., Ganis, J.J., Gozo,M., Khandan,T., Paktinat, M., Gilliland, D.G., and&nbsp;<strong><u>Gritsman, K</u>.</strong>&nbsp;Constitutively Active AKT Depletes Hematopoietic Stem Cells and Induces Leukemia in Mice.&nbsp;<strong><em>Blood&nbsp;</em></strong>2010; 115(7): 140615&nbsp;http://www.bloodjournal.org/content/115/7/1406</span></p&gt;
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>

EMR ID

73180

Is Open Scheduling

Off

David S. Geller

https://assets.montefioreeinstein.org/profiles/images/Geller_David_S_MD_2x.jpg

First Name

David

Last Name

Geller

NPI

1467437764

Faculty ID

10675

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Geller is a full-time faculty member of the Orthopaedic Surgery Department at Montefiore Medical Center and serves as the director of the Orthopaedic Oncology Service, managing both pediatric and adult patients.&nbsp; He is the co-director of Orthopaedic Surgery at the Montefiore Medical Center Moses Campus and currently serves as the Quality Improvement Officer for the Montefiore Cancer Committee.&nbsp; His clinical focus involves primary and metastatic bone and soft tissue tumors, with a secondary interest in joint replacement in the setting of extensive bone loss.&nbsp; He has experience in navigation-guided surgery, allograft reconstruction, endoprosthetic reconstruction, and use of custom or patient-tailored reconstructive prostheses.&nbsp; His research interests include expression patterns in osteosarcoma, surgical margins in osteosarcoma, novel drug screening methods and targeted therapy for osteosarcoma using novel therapeutic modalities.&nbsp; He is extensively involved in resident and medical student education.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Geller is an orthopaedic surgeon specializing in musculoskeletal oncology and joint replacement, and his practice encompasses adult and pediatric patients. Dr. Geller’s research interests include surface receptor expression in osteosarcoma and potential targeted therapies for the treatment of osteosarcoma. He has developed a novel murine xenograft model for osteosarcoma for the evaluation of surgical margins in osseous tumor surgery. His research additionally includes allograft bone reconstruction techniques, resonance frequency changes during joint reconstruction and pain management in the elderly orthopaedic population.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Orthopedic oncology, orthopedic surgery, bone and soft tissue sarcomas, benign bone and soft-tissue tumors, metastatic carcinoma on the bone </p>

Research Focus

<p>Osteosarcoma, with an interest in innovative treatment strategies for both local disease control and metastatic disease; evaluation of expression patterns in osteosarcoma and surgical margins using a xenograft osteosarcoma murine model; the functional role of bone morphogenetic proteins in osteosarcoma surgery; use of intraoperative navigation techniques for tumor surgery; tumorigenesis of osteosarcoma </p>

Elsevier Profile

PubMed.gov URL

Selected Publications

<ul>
<li>Morris J, Dutcher J, <strong>Geller DS</strong>. Revisiting the Orhtopaedic Management of Metastatic Renal Cell Carcinoma: Rationale for a More Aggressive Approach. <em>Current Orthopaedic Practice. </em>2013 Sept/Oct; 24(5):547-551.</li>
<li>Bekarev M, Elsinger EC, Villanueva-Siles E, Borzykowski RM, <strong>Geller DS.</strong> Synovial Sarcoma of the Foot. <em>Journal of Foot and Ankle Surgery</em>. 2013 Jul-Aug; 52(4):513-7. doi: 10.1053</li>
<li>Capogna BM, Lovy A, Blum Y, Kim SJ, Flesen UR, <strong>Geller DS.</strong> Infection Rate Following Total Joint Arthroplasty in the HIV Population. <em>Journal of Arthroplasty</em>. 2013 Sep; 28(8):1254-8. doi: 10.1016</li>
<li>Lall A, Hohn E, Kim M, Gorlick R, Abraham J, <strong>Geller DS</strong>. Comparison of Surface Area Across the Allograft-Host Junction Site Using Conventional and Navigated Osteotomy Technique. <em>Sarcoma</em>. 2012; 2012:197540.&nbsp;</li>
<li>Piperdi S, Austin-Page L, <strong>Geller DS</strong>, Ahluwalia M, Gorlick S, Gill J, Sellers R, Zhang W, Li N, Ching Sohak, Gorlick R. Beta-Catenin Does Not Confer Tumorigenicity when Introduced into Partially Transformed Human Mesenchymal Stem Cells.<em> Sarcoma</em>. 2012. Epub 2012 Oct 18.</li>
<li>Crocco L, Gorlick R,<strong> Geller DS</strong>. Current Practice Management Regarding Thromboembolic Prophylaxis Within the Pediatric Sarcoma Patient Population, <em>Journal of Pediatric Hematology/Oncology</em>.2012 Sep 19. [Epub ahead of print]</li>
<li>&nbsp;Hall GL, Villanueva-Siles E, Borzykowski RM, Gruson KI, Dorfman HD, <strong>Geller</strong> <strong>DS</strong>. Aspergillus osteomyelitis of the proximal humerus: a case report. <em>Skeletal Radiology</em>. 2012 Aug; 41(8):1021-5. Epub 2012 Mar 31.</li>
<li>Sambaziotis C, Plymale M, Lovy A, O&rsquo;Halloran K, McCulloch K, <strong>Geller DS</strong>. Pseudoaneurysm of the Distal Thigh after Manipulation of a Total Knee Arthroplasty. <em>Journal of Arthroplasty</em>. 2012 Aug; 27(7); 1414.</li>
<li>Shakked RJ, <strong>Geller DS</strong>, Gorlick R, Dorfman HD. Mesenchymal chondrosarcoma: Clinicopathologic study of 20 cases. <em>The Archives of Pathology &amp; Laboratory Medicine</em>.&nbsp; 2012 Jan; 136(1):61-75.</li>
<li>Hohn E, Garfein ES, Mehta KJ, <strong>Geller DS. </strong>Quadriceps Tendon Allograft Augmentation after Wide Excision of a Soft Tissue Sarcoma. <em>Current Orthopaedic Practice</em>. 2012 Jan/Feb; 23(1):68-71.</li>
<li>Singh CK, <strong>Geller DS. </strong>The Telescopic Mating Technique for Bulk Allograft Reconstruction. <em>Orthopaedics</em>. 2012 Feb; 35(2):118-124.</li>
<li>Sambaziotis C, Lovy A, Moadel RM, Chamarthy M, Glaser J, Jaini S, Villanueva-Siles E, <strong>Geller DS</strong>. Florine-18 Fluorodeoxyglucose Positron Emission Tomography for Osteochondromas Utilizing a Triple-Time Point Protocol.&nbsp; <em>Open Journal of Medical Imaging</em>. 2011 Dec; 1(2):15-20.</li>
<li>Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, <strong>Geller DS. </strong>Cell Surface Receptor Expression Patterns in Osteosarcoma. <em>Cancer.</em> 2011 Feb 1; 118(3):740-9.</li>
<li>Plymale M, Lovy A, Villanueva-Siles E, <strong>Geller DS.</strong> Isolated intra-articular pseudorheumatoid nodule of the knee.<em> Skeletal Radiology</em>. 2011 Apr; 40(4):463-6.</li>
<li>Green MC, Dorfman HD, Villanueva-Siles E, Gorlick RG, Thornhill BA, Weber RV, <strong>Geller DS. </strong>Aggressively Recurrent Infantile Myofibroma of the Axilla and Shoulder Girdle. A Case Report. <em>Skeletal Radiology</em>.2010 Mar; 40(3):357-61.</li>
<li><strong>Geller DS</strong>, Pope JB, Thornhill BA, Dorfman, HD. Cryptococcal pyarthrosis and sarcoidosis. <em>Skeletal Radiol</em>. 2009 Jul; 38(7):721-7.</li>
<li>Sah A, <strong>Geller DS</strong>, Mankin HJ, Delaney T, Rosenberg A, Wright C, Hornicek FJ. Malignant Transformation of Synovial Chondromatosis of the Shoulder to Chondrosarcoma - A Case Report," <em>Journal of Bone and Joint Surgery. </em>2007 Jun; 89(6):1321-8.</li>
<li><strong>Geller DS</strong>, Hornicek FJ, Mankin HJ, Raskin KA. &ldquo;Soft Tissue Sarcoma Resection Volume Associated with Wound-Healing Complications,&rdquo; <em>Clinical Orthopaedics and Related Research.</em> 2007; 457:182-5.</li>
<li>Ames JA, Abraham JA, <strong>Geller DS</strong>, Goldsmith J, Gebhardt MC.&nbsp; Proximal Tibial Lesion in a Young Adult: Early Diagnosis Allowing Unique Reconstruction.&nbsp; <em>The Orthopaedic Journal at Harvard Medical School.</em> 2006 Aug: 143-7.</li>
<li>Gardner MJ, Yacoubian S, <strong>Geller DS</strong>, Pode M, Mintz D, Helfet&nbsp; DL,&nbsp; Lorich DG. &ldquo;Prediction of Soft-Tissue Injuries in Schatzker II Tibial Plateau Fractures based on Measurements of Plain Radiographs,&rdquo; <em>Journal of Trauma-Injury Infection &amp; Critical Care</em>. 2006; 60(2):319-324.</li>
<li>Steinberg EL, <strong>Geller DS</strong>, Yacoubian SV, Shasha N, Dekel S, Lorich DG. &ldquo;Intramedullary Fixation of Tibial Shaft Fractures Using an Expandable Nail,&rdquo; <em>Journal of Orthopaedic Trauma.&nbsp; </em>2006 May; 20(5):303-9.</li>
<li>Gardner, MJ, Yacoubian S, <strong>Geller DS</strong>, Suk M, Mintz D, Potter H, Helfet DL, Lorich DG. &ldquo; The Incidence of Soft Tissue Injury in Operative Tibial Plateau Fractures,&rdquo; <em>Journal of Orthopaedic Trauma</em>.&nbsp; 2005; 19:79-84.</li>
<li>Lorich DG, Yacoubian SV, <strong>Geller DS</strong>. &ldquo;Intramedullary Fixation of Humeral Shaft Fractures Using an Inflatable Nail,&rdquo; <em>Orthopaedics</em>. 2003 Oct; 26(10):1011-4.</li>
<li>Lorich DG, <strong>Geller DS</strong>, Yacoubian SV, Leo AJ, Helfet DL. &ldquo;An Innovative Mode of Intramedullary Fixation,&rdquo; <em>International Review of Modern Surgery</em>, March 2002.</li>
<li>Westrich GH, <strong>Geller DS</strong>, O&rsquo;Malley MJ, Deland JT, Helfet DL. &ldquo;Anterior Iliac Crest Bone Graft Harvesting Using the Cortico-Cancellous Reamer System,&rdquo; <em>Journal of Orthopaedic Trauma</em>. 2001 Sep-Oct; 15(7):500-6.</li>
</ul>

EMR ID

4324

Biography

<p>David S. Geller is a board-certified orthopedic oncologist who specializes in the treatment of both pediatric and adult patients with bone and soft-tissue tumors. He has been a full-time faculty member at Montefiore since 2006. He is an Associate Professor of Orthopedic Surgery and Pediatrics at our Albert Einstein College of Medicine.</p><p>Dr. Geller is known for his expertise in musculoskeletal tumor surgery, with specific experience in bone and soft-tissue sarcomas, such as osteosarcoma, Ewing's sarcoma, liposarcoma and synovial sarcoma. He has extensive experience in managing patients with metastatic carcinoma of the bone as well. He routinely offers limb-salvage surgery using a wide array of reconstructive tools.</p><p>Dr. Geller earned his medical degree from Tel Aviv University's Sackler School of Medicine and completed an orthopedic surgery residency at Montefiore. He received his fellowship training from the Harvard Combined Orthopedic Oncology Program, which included Massachusetts General Hospital, Boston Children's Hospital, and Beth Israel Deaconess Medical Center.</p><p>Dr. Geller serves as the Associate Director of the Musculoskeletal Oncology Research Laboratory at Montefiore. He leads numerous translational research efforts designed to investigate the pathophysiology and molecular mechanisms of bone and soft tissue cancers. He is interested in improved surgical techniques and novel therapeutic approaches for primary malignant bone tumors. He is actively involved in collaborative clinical trials both nationally and internationally.</p><p>Dr. Geller is an active member of the American Academy of Orthopedic Surgeons, Muskuloskeletal Tumor Society, Connective Tissue Oncology Society, Children's Oncology Group, American Orthopedic Association, and the American Association for Cancer Research.</p>

Is Open Scheduling

Off